Cytocare Inc. (NASDAQ:CYTI) said that it has acquired exclusive worldwide rights to diagnostic, prognostic and therapeutic uses of certain hybridoma cell lines and murine monoclonal antibodies specific for prostate cancer.
The patented molecules were licensed from the Sloan-Kettering Institute for Cancer Research. Irvine, Calif.-based Cytocare is developing a family of molecules to diagnose and treat benign prostatic hypertrophy and prostate cancer. The company's shares closed unchanged at $1.88 on Tuesday.
(c) 1997 American Health Consultants. All rights reserved.